Coherus Delivers First US Rival To Neulasta OnPro, As Biosimilar Interest Peters Out
California-Based Firm Now Offers Full Suite Of Pegfilgrastim Products With Autoinjector
“Innovating cancer care for patients is a winning strategy,” Coherus said as it delivered on the first US biosimilar version of Amgen’s dominant pegfilgrastim formulation, using an on-body device to deliver the medication, months after a protracted FDA approval.
